Publication: Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
Loading...
Identifiers
Date
2018-01-12
Authors
Pavel, Marianne
Gross, David J
Benavent, Marta
Perros, Petros
Srirajaskanthan, Raj
Warner, Richard R P
Kulke, Matthew H
Anthony, Lowell B
Kunz, Pamela L
Hörsch, Dieter
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and well tolerated in the phase 3 TELESTAR study in patients with carcinoid syndrome (CS) experiencing ≥4 bowel movements per day (BMs/day) while on somatostatin analogs (SSAs). TELECAST, a phase 3 companion study, assessed the safety and efficacy of telotristat ethyl in patients with CS (diarrhea, flushing, abdominal pain, nausea or elevated urinary 5-hydroxyindoleacetic acid (u5-HIAA)) with
Description
MeSH Terms
Adult
Aged
Aged, 80 and over
Diarrhea
Double-Blind Method
Female
Humans
Hydroxyindoleacetic Acid
Male
Malignant Carcinoid Syndrome
Middle Aged
Phenylalanine
Pyrimidines
Somatostatin
Treatment Outcome
Aged
Aged, 80 and over
Diarrhea
Double-Blind Method
Female
Humans
Hydroxyindoleacetic Acid
Male
Malignant Carcinoid Syndrome
Middle Aged
Phenylalanine
Pyrimidines
Somatostatin
Treatment Outcome
DeCS Terms
CIE Terms
Keywords
5-HIAA, carcinoid syndrome, metastatic neuroendocrine tumor, serotonin, somatostatin analog